Sinphar Pharmaceutical CoTPE:1734 -1.08%81 EBITDA Margin % is 20.20% as of Dec. 2025, which is 90% above its 10-year median of 10.62. GuruFocus rates TPE:1734 with a GF Score™ of 81/100 and a GF Value™ of NT$33.13 (Fairly Valued). The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, Sinphar Pharmaceutical Co ranks better than 83.05% on this metric.
Sinphar Pharmaceutical Co (TPE:1734) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sinphar Pharmaceutical Co EBITDA Margin % Related Terms
Sinphar Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1734 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Sinphar Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinphar Pharmaceutical Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinphar Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sinphar Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinphar Pharmaceutical Co (TPE:1734) has a EBITDA Margin % of 20.20% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sinphar Pharmaceutical Co and its competitors. This is 90% above median its historical median of 10.62. Over the past decade, Sinphar Pharmaceutical Co's EBITDA Margin % has ranged from 4.51 to 20.46. According to the industry distribution chart, Sinphar Pharmaceutical Co ranks #160 out of 944 companies in the Biotechnology industry, placing it in the top 16.9%.
Is Sinphar Pharmaceutical Co's EBITDA Margin % too high?
Sinphar Pharmaceutical Co's current EBITDA Margin % of 20.20% is 90% above median its 10-year median of 10.62. Over the past 10 years, this metric has ranged from a low of 4.51 to a high of 20.46. Based on the distribution chart, Sinphar Pharmaceutical Co ranks #160 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinphar Pharmaceutical Co ranks #160 out of 944 companies for EBITDA Margin %. This places Sinphar Pharmaceutical Co in the top 17% of its industry — outperforming the majority of peers. Historically, Sinphar Pharmaceutical Co's own EBITDA Margin % has ranged from 4.51 to 20.46 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sinphar Pharmaceutical Co and its competitors. Sinphar Pharmaceutical Co's current EBITDA Margin % is 20.20%, which is 90% above median its own 10-year median of 10.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.13, compared to a current price of NT$32.00 — trading 3.4% below its estimated fair value. The current EBITDA Margin % is 20.20%, which is 90% above median its 10-year median of 10.62. Sinphar Pharmaceutical Co's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current EBITDA Margin % is 20.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$32.00 is trading 3.4% below its estimated GF Value™ of NT$33.13.
GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TPE:1734:
EBITDA Margin %: 20.20% (90% above median its 10-year median of 10.62)
GF Value™: NT$33.13 vs. price of NT$32.00 (3.4% below fair value)
No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
81GF Score
Get the complete analysis for TPE:1734
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1734 has been successfully added to your 
